FDA says pause in use of J&J vaccine to investigate clots will likely last 'matter of days'
WASHINGTON — The Food and Drug Administration says it expects a short pause of Johnson & Johnson vaccines while regulators investigate reports of potentially dangerous clots in a small number of patients.
Dr. Janet Woodcock, the agency’s acting commissioner, says, “We expect it to be a matter of days for this pause.”
The U.S. FDA and the Center for Disease Control and Prevention recommended the pause Tuesday to investigate unusual clots in six women that occurred 6 to 13 days after vaccination with the J&J vaccine. The clots occurred in veins that drain blood from the brain and occurred together with low platelets. All cases were in women between the ages of 18 to 48.
Nearly 7 million J&J doses have been administered in the U.S., almost all without serious side effects.
Regulators say they want to educate patients and medical professionals about spotting and treating the clots. The clots were observed along with reduced platelet counts, making the usual treatment for blood clots, the blood thinner heparin, potentially “dangerous.”
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
School shooting in Russia kills 8
Another delay in vote to legalize marijuana in Louisiana, bill to be...
As Colonial Pipeline remains offline, 'spotted' fuel outages possible at La. gas...
As businesses struggle to hire workers, organization pushes for end to federal...
Woman shot after finding burglar outside her home; latest in rash of...
LSU pitcher Matt Beck gets his moment at the plate
Brusly baseball needs extra innings to win regional series with Jennings.
Southern Athletic Director Roman Banks talks about coaching search
Drew Brees and Sean Payton enjoy the Zurich Classic
Legendary Parkview coach Kenny Guillot passes away at 76